Rituximab Plus Lenalidomide Combination Therapy for Patients With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT)
Read time: 1 mins
Last updated:5th Sep 2013
This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.
|Study start date||2013-09-05|